Design Therapeutics (DSGN) Change in Cash (2020 - 2026)
Design Therapeutics recorded quarterly Change in Cash of -$4.1 million in Q1 2026, down 331.11% quarter-over-quarter from $1.8 million in Q4 2025, and up 54.07% year-over-year from -$2.7 million in Q1 2025.
Design Therapeutics' Change in Cash history runs 7 years deep, the most recent figure standing at -$4.1 million for Q1 2026.
- In Q1 2026, Change in Cash rose 54.07% year-over-year to -$4.1 million; the TTM figure through Mar 2026 stood at -$897000.0 (up 94.3% YoY), while the FY2025 annual figure was -$5.7 million, down 518.71% from the prior year.
- Change in Cash came in at -$4.1 million for Q1 2026 at Design Therapeutics, down from $1.8 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $16.3 million in Q2 2024 to a low of -$167.7 million in Q2 2022.
- A 5-year average of -$16.8 million and a median of -$4.6 million in 2025 frame the typical range for Change in Cash.
- On a YoY basis, Change in Cash climbed as much as 1111.29% in 2024 and fell as far as 2163.22% in 2024.
- Design Therapeutics' Change in Cash stood at -$16.0 million in 2022, then jumped by 57.91% to -$6.7 million in 2023, then slipped by 15.17% to -$7.8 million in 2024, then soared by 122.77% to $1.8 million in 2025, then tumbled by 331.11% to -$4.1 million in 2026.
- According to Business Quant data, Change in Cash over the past three periods registered -$4.1 million, $1.8 million, and -$4.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 623.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 417.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -153.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 53.61 Mn |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - | -4.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.09 Mn |
| Dec 31, 2025 | 1.77 Mn |
| Sep 30, 2025 | -4.62 Mn |
| Jun 30, 2025 | 6.04 Mn |
| Mar 31, 2025 | -8.90 Mn |
| Dec 31, 2024 | -7.77 Mn |
| Sep 30, 2024 | -15.37 Mn |
| Jun 30, 2024 | 16.30 Mn |
| Mar 31, 2024 | 8.20 Mn |
| Dec 31, 2023 | -6.74 Mn |
| Sep 30, 2023 | 745,000.00 |
| Jun 30, 2023 | -1.61 Mn |
| Mar 31, 2023 | 2.31 Mn |
| Dec 31, 2022 | -16.02 Mn |
| Sep 30, 2022 | -77.14 Mn |
| Jun 30, 2022 | -167.66 Mn |
| Mar 31, 2022 | -11.26 Mn |
| Dec 31, 2021 | -59.09 Mn |
| Sep 30, 2021 | -13.18 Mn |
| Jun 30, 2021 | -29.86 Mn |
| Mar 31, 2021 | 398.31 Mn |
| Dec 31, 2020 | -845,000.00 |
| Sep 30, 2020 | 1.33 Mn |
| Jun 30, 2020 | -806,000.00 |
| Mar 31, 2020 | 2.63 Mn |